Table 1. Baseline characteristics of the participants in the DPS and FINRISK1992 studies by glucose tolerance.
| Study: | DPS | DPS | FINRISK | FINRISK | FINRISK | FINRISK |
| Glucose tolerance: | IGT (intervention) | IGT (control) | Normal | IGT | ST2DM | T2DM |
| Number of subjects: n | 257 | 248 | 1570 | 183 | 59 | 69 |
| Age, years | 55.4±7.3 | 55.0±6.9 | 53.7±6.0 | 55.8±5.8 | 55.9±5.4 | 55.6±6.3 |
| Sex, % men | 34.2 | 31.5 | 40.9 | 50.6 | 55.2 | 50.7 |
| BMI, kg/m2 | 31.4±4.6 | 31.2±4.5 | 26.8±3.9 | 29.8±5.2 | 31.7±6.1 | 30.5±4.9 |
| Smoking, % | 7.0 | 7.3 | 20.3 | 24.0 | 23.7 | 14.5 |
| Fasting glucose, mmol/l | 6.1±0.8 | 6.2±0.7 | 5.4±0.6 | 6.0±0.6 | 7.8±2.2 | 10.4±3.0 |
| 2-h glucose, mmol/l | 8.9±1.5 | 8.9±1.5 | 5.5±1.1 | 8.8±0.9 | 14.0±3.8 | - |
| Total cholesterol, mmol/l | 5.6±1.0 | 5.6±0.9 | 5.9±1.0 | 6.0±1.1 | 6.2±1.2 | 5.8±1.3 |
| HDL cholesterol, mmol/l | 1.21±0.31 | 1.22±0.28 | 1.42±0.35 | 1.25±0.31 | 1.19±0.29 | 1.14±0.31 |
| Triglycerides, mmol/l | 1.69±0.80 | 1.76±0.76 | 1.49±0.86 | 2.17±1.52 | 2.74±1.82 | 2.78±1.92 |
| Systolic blood pressure, mmHg | 139.6±17.7 | 136.2±17.4 | 140.3±19.4 | 148.8±19.5 | 150.2±21.1 | 145.6±20.8 |
| Diastolic blood pressure, mmHg | 85.7±9.4 | 85.6±10.0 | 84.9±11.0 | 88.8±11.0 | 88.3±12.9 | 85.1±9.8 |
| Drug treatment for lipid abnormalities, % | 4.3 | 6.1 | 2.3 | 2.8 | 1.7 | 10.1 |
| Drug treatment for elevated blood pressure, % | 27.7 | 31.5 | 13.5 | 31.9 | 37.9 | 36.8 |
| Baseline CVD*, % | 8.2 | 8.1 | 9.0 | 19.7 | 25.4 | 34.8 |
| Framingham 10-year CVD-probability, %: | 14.3 | 13.2 | 14.4 | 19.4 | 31.0 | 29.3 |
*
Values are means±standard deviation unless otherwise noted. Baseline CVD: At least one cardiovascular event (ICD 8 and 9 codes: 401–449; ICD 10 codes : I10–I79) according to the Finnish Hospital discharge register before participation in the DPS or FINRISK studies.